Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Increased intratumoral IL-22-producing CD4 + T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival

doi: 10.1007/s00262-012-1241-5

Figure Lengend Snippet: IL-22+CD4+ T cells accumulate in tumor tissues and IL-22+CD4+ T-cell percentage predicts patient survival. a, b Distribution of IL-22+CD4+ T cells in GC patients. Results are expressed as the percentage of IL-22+CD4+ T cells in CD4+ T cells (a) or in CD3+ cells (b) in different tissues. c Dot plots of intracellular cytokine staining for IL-22+CD4+ T cells by gating on lymphocytes, CD3+ cells, and CD4+ T cells. Numbers indicate relative percentages in CD4+ T cells. d Immunofluorescence staining for intratumoral IL-22+CD4+ cells (left 1 panel: original magnification, ×4,000). The arrows indicate representative positive cells in tumor tissues. The green signal represents the staining of IL-22, the red signal represents the staining of CD4, and the blue signal represents the DAPI-stained nuclei (right 4 panels: original magnification, ×100,000). e Percentages of IL-22+CD4+ T cells in CD4+ T cells among TNM stage were compared. f Kaplan–Meier curve for overall survival by median IL-22+CD4+ T-cell percentages. Survival significantly decreased as a function of the percentage of IL-22+CD4+ T cells in CD4+ T cells increased. The horizontal bars in (a, b, e) represent mean values. Each ring in (a, b, e) represents one patient

Article Snippet: Sections were incubated with goat anti-human IL-22 antibody (Ab) (R&D Systems, Minneapolis, MN, USA) diluted in 5 % rabbit serum.

Techniques: Staining, Immunofluorescence

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Increased intratumoral IL-22-producing CD4 + T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival

doi: 10.1007/s00262-012-1241-5

Figure Lengend Snippet: IL-22+IL-17+CD4+, IL-22+IL-17−CD4+, IL-22+IFN-γ+CD4+, and IL-22+ IFN-γ−CD4+ T cells accumulate in tumor tissues. a, c Distribution of IL-22+CD4+ T-cells subsets in GC patients. Results are expressed as the percentage of IL-22+IL-17+CD4+ and IL-22+IL-17−CD4+ T cells in CD4+ T cells (a) or IL-22+IFN-γ+CD4+ and IL-22+IFN-γ−CD4+ T cells in CD4+ T cells (c) in different tissues. b, d Dot plots of intracellular cytokine staining for IL-22+IL-17+CD4+ and IL-22+IL-17−CD4+ T cells (b) or IL-22+IFN-γ+CD4+ and IL-22+IFN-γ−CD4+ T cells (d) by gating on CD4+ T cells. Numbers indicate relative percentages in CD4+ T cells. The horizontal bars in (a, c) represent mean values. Each ring in (a, c) represents one patient

Article Snippet: Sections were incubated with goat anti-human IL-22 antibody (Ab) (R&D Systems, Minneapolis, MN, USA) diluted in 5 % rabbit serum.

Techniques: Staining

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Increased intratumoral IL-22-producing CD4 + T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival

doi: 10.1007/s00262-012-1241-5

Figure Lengend Snippet: Th22 cells and IL-22+IL-17+IFN-γ+CD4+ T cells accumulate in tumors, and Th22 cells correlate with tumor stage and survival in GC patients. a The percentage of IL-22+IL-17−IFN-γ−CD4+ (Th22), IL-22+IL-17+IFN-γ−CD4+, IL-22+IL-17−IFN-γ+CD4+, and IL-22+IL-17+IFN-γ+CD4+ T cells in CD4+ T cells in non-tumor or tumor tissues (n = 76). b Dot plots of intracellular cytokine staining for IL-22+IL-17−IFN-γ−CD4+ (Th22), IL-22+IL-17+IFN-γ−CD4+, IL-22+IL-17−IFN-γ+CD4+, and IL-22+IL-17+IFN-γ+CD4+ T cells by gating on CD4+ T cells. Numbers indicate relative percentages in CD4+ T cells. c Percentages of Th22 cells in CD4+ T cells among TNM stage were compared. d Kaplan–Meier curve for overall survival by median Th22-cell percentages. Survival significantly decreased as a function of the percentage of Th22 cells increased. The horizontal bars in c represent mean values. Each ring in (c) represents one patient

Article Snippet: Sections were incubated with goat anti-human IL-22 antibody (Ab) (R&D Systems, Minneapolis, MN, USA) diluted in 5 % rabbit serum.

Techniques: Staining

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Increased intratumoral IL-22-producing CD4 + T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival

doi: 10.1007/s00262-012-1241-5

Figure Lengend Snippet: Intratumoral IL-22+CD4+ T cells show an IL-17/IFN-γ co-expression and memory phenotype, and IL-22+CD4+ T-cell differentiation is induced by IL-6 and IL-23 in the presence of monocytes. a Multicolor flow cytometry for the co-expression of cytokine profile, CD45RA, CD62L, and the markers associated with T-cell activation/effector function and immune suppression on intratumoral IL-22+CD4+ T cells. b, c Peripheral CD4+ cells were co-cultured for 5 days with or without autologous peripheral CD14+ monocytes at 2:1 ratio supplemented with different concentrations of IL-6 or IL-23. Results are expressed as the percentage of IL-22+CD4+, IL-22+IL-17+CD4+, IL-22+IL-17−CD4+, IL-22+IFN-γ+CD4+, and IL-22+IFN-γ−CD4+ T cells in CD4+ T cells (b). Production of IL-22 in the co-culture systems was detected by ELISA in the culture supernatants (c). * indicates P < 0.05, ** indicates P < 0.01, n.s. indicates P > 0.05 for groups connected by horizontal lines compared in (c), or compared with media controls in (c). Results above are representative of 3 independent experiments

Article Snippet: Sections were incubated with goat anti-human IL-22 antibody (Ab) (R&D Systems, Minneapolis, MN, USA) diluted in 5 % rabbit serum.

Techniques: Expressing, Cell Differentiation, Flow Cytometry, Activation Assay, Cell Culture, Co-Culture Assay, Enzyme-linked Immunosorbent Assay

Journal: Cell Reports Medicine

Article Title: mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

doi: 10.1016/j.xcrm.2023.100978

Figure Lengend Snippet:

Article Snippet: Anti-mouse affinity purified IL-22 , R and D Systems , Polyclonal; Cat# AF582, RRID: AB_355457.

Techniques: In Vivo, Activation Assay, Affinity Purification, Virus, Recombinant, Staining, Membrane, Plasmid Preparation, SYBR Green Assay, Cell Isolation, Enzyme-linked Immunosorbent Assay, Transgenic Assay, Control, Negative Control, Retroviral, Software